- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02208986
GnRHa Trigger in Asian Oocyte Donors- a Dose Finding Study
GnRHa Trigger in Asian Oocyte Donors Co-treated With a GnRH Antagonist - a Dose Finding Study
The aim of this randomized single center study is to explore the most optimal dose of GnRHa used for triggering of final oocyte maturation in IVF. The study group will consist of oocyte donors who have GnRHa trigger as a standard trigger concept.
Hypothesis: In an Asian oocyte donor population, the use of 0.2 mg, 0.3mg or 0.4 mg of GnRHa will lead to the retrieval of comparable numbers of mature oocytes (MII) and good quality embryos. Moreover, the reproductive outcome in the recipients will be similar regardless of the dose of GnRHa used for trigger.
Study Overview
Detailed Description
Methods
A randomized controlled single center study. All oocyte donors, fulfilling the inclusion criteria, will be eligible for inclusion after randomization.
Stimulation, monitoring, oocyte pick-up in donors and embryo transfer in recipients On day two of the cycle, - i.e. prior to commencing stimulation with long acting FSH (Elonva) - donors will be randomized to one of three groups, using different doses of GnRHa (Triptorelin) for trigger. Stimulation will be performed according to the standard stimulation protocol of the clinic, using Elonva followed by co-treatment with a GnRH antagonist from day 5 of stimulation . The dose of Elonva used for stimulation will be either 100 or 150 µg according to the weight of the patient. The first transvaginal ultrasound scan (TVUS) will be performed after seven or eight days after the Elonva depot injection. As soon as two follicles have reached a size of ≥ 17mm, triggering of final oocyte maturation will be performed with one single bolus of Triptorelin, 0.2 mg, 0.3mg or 0.4 mg. The timing of the trigger will be 6 AM for all groups and the oocyte pick-up (OPU) will be performed after 34 hours, according to the usual practice of the clinic. Importantly, each patient will be asked to check the presence of an LH surge via a urine LH detection kit at 4 hours after the trigger bolus has been administered. Embryo transfer will be performed on day two in all recipients.
Study group I Stimulation according to the abovementioned and ovulation trigger with 0.2mg Triptorelin. All other procedures will be performed according to the practice of the clinic.
Study group II Stimulation according to the abovementioned and ovulation trigger with 0.3mg Triptorelin. All other procedures will be performed according to the practice of the clinic.
Study group III Stimulation according to the abovementioned and ovulation trigger with 0.4mg Triptorelin. All other procedures will be performed according to the practice of the clinic.
Randomization Randomization will be performed using sealed envelopes developed via a computer generated list with blocks of twelve. The randomization will be performed on day two of the cycle. Doctors will be blinded to the randomization, but not patients and nurses.
Follicular fluid (FF) collection FF from the first punctured follicle on each side will be collected and cryo-preserved at -20 degrees for subsequent analysis of steroids.
Granulosa cell gene-expression analysis Cumulus and mural granulosa cells will be preserved and snap-frozen from a sub-group of 10 patients in each group. The primary subsequent analysis will focus on possible differences in LHR gene expression according to GnRHa trigger dose.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ho Chi Minh
-
Ho Chi Minh City, Ho Chi Minh, Vietnam
- My Duc Hospital, IVFMD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Oocyte donors who meet the following criteria:
- Age 18 - 35
- BMI < 28kg/m2
- Normal ovarian reserve, defined by AMH > 1.25 ng/ml or AFC ≥ 6 measured within two months prior to stimulation start
- Receiving GnRH-antagonist protocol for ovarian stimulation,
- Agreement to participate in the study, and to disclose any medical events to the investigator. The subject must be willing and able to comply with the protocol requirements for the duration of the study.
- Have given written informed consent with the understanding that the subject may withdraw consent at any time without prejudice to future medical care.
Exclusion Criteria:
- Previous poor response (≤ 3 oocytes) after high dose FSH stimulation
- Chronical medical conditions like Diabetes, Crohns disease, Thyroid disease, Hepatitis B and Sexually Transmitted Diseases Simultaneous participation in an interventional clinical trial.
- Concommitant use of either LH or hMG/uFSH preparations in study cycle
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 0.2mg Triptorelin
Ovulation trigger with 0.2mg Triptorelin in one subcutaneous injection.
|
Triptorelin is given by s.c injection for ovulation triggering.
Other Names:
|
Active Comparator: 0.3mg Triptorelin
Ovulation trigger with 0.3mg Triptorelin in one subcutaneous injection.
|
Triptorelin is given by s.c injection for ovulation triggering.
Other Names:
|
Active Comparator: Active Comparator: 0.4mg Triptorelin
Ovulation trigger with 0.4mg Triptorelin in one subcutaneous injection.
|
Triptorelin is given by s.c injection for ovulation triggering.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of mature oocytes
Time Frame: 30 minutes after oocyte retrieval completed
|
30 minutes after oocyte retrieval completed
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Day of bleeding after oocyte pick-up
Time Frame: in 2 weeks after oocyte pick-up
|
in 2 weeks after oocyte pick-up
|
Clinical pregnancy
Time Frame: 5 weeks after oocyte pick-up
|
5 weeks after oocyte pick-up
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Lan TN Vuong, MD, Department of Obstetrics and Gynecology, University of Medicine and Pharmacy HCMC, Ho Chi Minh City, Vietnam
- Principal Investigator: Peter Humaidan, MD, Aarhus University Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NCKH/CGRH_01_2014
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Normal Oocyte Donors
-
CRG UZ BrusselRecruitingOocyte Donation | Oocyte DonorsBelgium
-
Embryolab Fertility ClinicART Fertility Clinics LLCRecruitingOvarian Stimulation | Oocyte Donors | Human Chorionic GonadotropinGreece
-
National Cancer Institute (NCI)Completed
-
AmgenCompleted
-
Institut Universitari DexeusCompletedCircadian Rhythm | Controlled Ovarian Stimulation | Oocyte Donors | Progesterone Variation on Trigger DaySpain
-
National Institute of Allergy and Infectious Diseases...CompletedLiving Donors | Tissue Donors
-
Chinese University of Hong KongRecruiting
-
Acibadem UniversityCompleted
-
Ibn Sina HospitalBanon IVF Center Assiut, Egypt; Al Baraka Fertility HospitalCompleted
-
Center for Reproductive an Genetic HealthUniversity College, LondonUnknownOocyte CompetenceUnited Kingdom
Clinical Trials on Triptorelin
-
Nanjing UniversityUnknownPolycystic Ovary Syndrome | In Vitro FertilizationChina
-
Aristotle University Of ThessalonikiEugonia IVF Unit, Athens, GreeceUnknown
-
ChenshilingNational Natural Science Foundation of China; Comprehensive Strategic Cooperation... and other collaboratorsUnknown
-
IVI MadridCompletedOvarian Hyperstimulation SyndromeSpain
-
Masaryk UniversityMinistry of Health, Czech RepublicCompletedHodgkin Disease | Hodgkin LymphomaCzech Republic
-
Universitair Ziekenhuis BrusselUniversitaire Ziekenhuizen KU LeuvenRecruitingBreast Cancer FemaleBelgium
-
Kaunas University of MedicineUnknown
-
Parc de Salut MarCompletedHealthy VolunteersSpain
-
Tampere University HospitalCompleted